Product
Supplier
Encyclopedia
Inquiry
Odanacatib 603139-19-1 buy - large image1
Odanacatib 603139-19-1 buy - image1
Odanacatib 603139-19-1 buy - image2

Odanacatib 603139-19-1

24 Inquiries

Unit Price:

$1/UNIT FOB

Get Latest Price
CAS No.:

603139-19-1

Grade:

Pharmaceutical Grade

Content:

99%

Port:

cn

Packaging:

foil bag

Price valid (until):

2026-11-10

Company Type:
Manufactory
Location:
China
Payment Terms:
L/C,100% TT in advance
Average Lead Time:
3 days
Qualification:
Main Products:

Avanafil,Tirzepatide,Semaglutide,Pregabalin,Nootropics,MT2

  • Product Description

  • Seller Information

  • Inquiry History

  • Description

    Odanacatib is a potent, selective, and neutral inhibitor of cathepsin K. Possesses favorable pharmacokinetic properties.

    ECHEMI Editorial Reference
    Odanacatib (MK-0822) is a potent and selective inhibitor of cathepsin K, with an IC50 of 0.2 nM for human cathepsin K.
    Odanacatib is an inhibiter of cathepsin K which was originally developed be Merck & Co as a new treatment for osteoporosis. The drug made it to phase III trials before abandoned due to increased stroke.|Odanacatib is an inhibitor of cathepsin K with potential anti-osteoporotic activity. Odanacatib selectively binds to and inhibits the activity of cathepsin K, which may result in a reduction in bone resorption, improvement of bone mineral density, and a reversal in osteoporotic changes. Cathepsin K, a tissue-specific cysteine protease that catalyzes degradation of bone matrix proteins such as collagen I/II, elastin, and osteonectin plays an important role in osteoclast function and bone resorption.

    Basic Info
    Product Name:

    Odanacatib

    Other Name:

    Pentanamide,N-(1-cyanocyclopropyl)-4-fluoro-4-methyl-2-[[(1S)-2,2,2-trifluoro-1-[4′-(methylsulfonyl)[1,1′-biphenyl]-4-yl]ethyl]amino]-,(2S)-;(2S)-N-(1-Cyanocyclopropyl)-4-fluoro-4-methyl-2-[[(1S)-2,2,2-trifluoro-1-[4′-(methylsulfonyl)[1,1′-biphenyl]-4-yl]ethyl]amino]pentanamide;Odanacatib;N1-[(1-Cyanocyclopropyl)-4-fluoro-N2-[(1S)-2,2,2-trifluoro-1-[4-methylsulfonyl]-1,1′-biphenyl-4-yl] ethyl]-L-leucinamide

    CAS No.:

    603139-19-1

    Molecular Formula:

    C25H27F4N3O3S

    InChIKeys:

    InChIKey=FWIVDMJALNEADT-SFTDATJTSA-N

    Molecular Weight:

    525.564

    Exact Mass:

    525.56

    EC Number:

    1533716-785-6

    UNII:

    N673F6W2VH

    DSSTox ID:

    DTXSID40209075

    NCI Thesaurus Code:

    C66981

    Categories:

    Inhibitor Drugs

    Characteristics
    PSA:

    107

    XLogP3:

    4.1

    Density:

    1.4±0.1 g/cm3

    Melting Point:

    223-224 °C

    Boiling Point:

    681.6±55.0°C at 760 mmHg

    Flash Point:

    366.0±31.5 °C

    Refractive Index:

    1.563

    Hazard Identification

    Classification of the substance or mixture

    Specific target organ toxicity – repeated exposure, Category 1

    GHS label elements, including precautionary statements

    Pictogram(s)
    Signal word

    Danger

    Hazard statement(s)

    H373 May cause damage to organs through prolonged or repeated exposure

    Precautionary statement(s)
    Prevention

    P260 Do not breathe dust/fume/gas/mist/vapours/spray.

    P264 Wash ... thoroughly after handling.

    P270 Do not eat, drink or smoke when using this product.

    Response

    P319 Get medical help if you feel unwell.

    Storage

    none

    Disposal

    P501 Dispose of contents/container to an appropriate treatment and disposal facility in accordance with applicable laws and regulations, and product characteristics at time of disposal.

    Other hazards which do not result in classification

    no data available

    Handling and Storage

    Precautions for safe handling

    Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.

    Conditions for safe storage, including any incompatibilities

    Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.

  • Seller Information
    Business Type:

    Manufactory

    Main Products:

    Avanafil,Tirzepatide,Semaglutide,Pregabalin,Nootropics,MT2

    Location:

    Room 1-2208, Lianhecaifu Square, No2177, Tianchen Road, Gaoxin District, Jinan City, Shandong Province, China

    Payment Terms:

    L/C,100% TT in advance

    Average lead Time:

    3 days

    Total Annual Revenue:

    $1 million-$2.5 million

    Total Employees:

    11-50

    Year of Establishment:

    2012

    Company Certificates
    • Jinan Million Pharmaceutical Co., Ltdbusiness license business license

    Founded in 2012, Jinan Million Pharmaceutical Co., Ltd (Jinan Milin Pharmaceutical Co., Ltd) is a modern pharmaceutical enterprise guided by innovation. Million pharm has excellent research and development capabilities and complete industrial bases with international quality management system. It is dedicated to the research, development, production and customization of pharmaceuticals and advanced pharmaceutical intermediates.
     
    Jinan Million Pharmaceutical Co., Ltd has been focusing on the research of Cerebro-cardiovascular drugs, Central nervous system drugs, Anti-cancer drugs, Antibacterial drugs and others for 12 years; the products are: Apixaban, Lurasidone, Bexagliflozin, Votioxitine, Loxo-292/Selpercatinib, Baricitinib and intermediates. Million has worked with reputable customers, like METROCHEM API PVT LTD; BDR LIFESCIENCES PVT.LTD; INCETPAT PHARM; SRINI CHEM; EVA PHARMA; PHARMAFFILIATES ANALYTICS & SYNTHETICS (P) LTD; ....from India, Egypt, Canada...



    Jinan Million Pharmaceutical Co., Ltd has a 1,500㎡ R&D center in the Zhongguancun E Valley (Qihe) Incubator, equipped with complete test equipment, such as high-performance liquid chromatography, nuclear magnetic resonance spectrometer, liquid chromatography mass spectrometer, automatic polarimeter, etc., which can meet the needs of various  laboratory scale tests in different conditions. The pilot workshop is equipped with 50L and 100L glass reactors, high and low temperature equipment, etc., which can support organic chemical reactions at -100°C or 200°C. In addition, Million has a production site in Linyi city with many independent production lines, such as: production line of Apixabn intermediate 20 tons/year, production line of Lurasidon intermediate 10 tons/year, which can meet the commercial production of various products.
     
    The technical team is composed of high-level talents in major of pharmacy, bio-pharmaceutical or chemical synthesis, of which 10% has doctor’s degree and 15% has master’s degree. The team members are young and energetic with innovative spirit and willing to overcome obstacles.
     
    Jinan Million Pharmaceutical Co., Ltd adheres to the business philosophy of "dedication and innovation", insists on pioneering and innovating, constantly improves the quality system, and vigorously trains technical and management talents to build an elite team and serves customers better. Looking forward to cooperate with you for joint development and common progress.

  • Inquiry History
    24 Inquiries
    Country Product Purchase Quantity Date Posted
    United States

    Odanacatinib

    1 G Sep 6, 2026
    Germany

    Odanacatib

    3 G Aug 1, 2026
    Germany

    Odanacatib

    1 G Oct 15, 2026
    United Kingdom

    odanacatib

    1 G Sep 1, 2026
    United Kingdom

    Odanacatib

    2 G Aug 3, 2026
    United States

    odanacatib

    20 G Aug 2, 2026
    Switzerland

    Odanacatib

    10 G Jul 31, 2026
    India

    MK-0822

    500 G Jul 24, 2026
    Denmark

    Odanacatib

    1 G Sep 27, 2026
    United States

    Odanacatib

    1 G Sep 14, 2026
    France

    Odanacatib

    750 MG Sep 13, 2026
    Canada

    Odanacatib

    1 G Sep 8, 2026
    United States

    Odanacatib

    3 G Sep 7, 2026
    United States

    Odanacatib

    1 G Aug 3, 2026
    Montenegro

    Odanacatib

    10 G Jul 22, 2026
    Australia

    Odanacatib

    100 G Jul 22, 2026
    Australia

    Odanacatib

    1 G Jul 21, 2026
    United Kingdom

    Odanacatib

    100 G Sep 20, 2026
    Romania

    Odanacatib

    9 G Sep 14, 2026
    United States

    odanacatib

    1 G Sep 6, 2026
    • 1
    • 2
    • Go to Page Go
    Post an enquiry for this product
pic ×

Scan the QR Code to Share

All products displayed on this website are only for non-medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.

According to relevant laws and regulations and the regulations of this website, units or individuals who purchase hazardous materials should obtain valid qualifications and qualification conditions.

The information shown above is provided by the enterprise itself, and the authenticity, accuracy and legitimacy of the content are the responsibility of the publishing company. ECHEMI does not bear any guarantee responsibility for this. Please be aware that risks in internet transactions objectively exist.

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.